Reducing the risk of stroke in type 2 diabetes: pathophysiological and therapeutic perspectives.
about
Glucagon-like receptor 1 agonists and DPP-4 inhibitors: potential therapies for the treatment of strokePituitary Adenlylate Cyclase Activating Peptide Protects Adult Neural Stem Cells from a Hypoglycaemic milieuGut-brain connection: The neuroprotective effects of the anti-diabetic drug liraglutideExendin-4 reduces ischemic brain injury in normal and aged type 2 diabetic mice and promotes microglial M2 polarization.Hyperglycemia as a Risk Factor of Ischemic StrokeGlucagon-like peptide-1 receptor activation reduces ischaemic brain damage following stroke in Type 2 diabetic ratsPlatelet isoprostane overproduction in diabetic patients treated with aspirin.Neural stem cells in the diabetic brainIntranasal Delivery of Exendin-4 Confers Neuroprotective Effect Against Cerebral Ischemia in Mice.The DPP-4 inhibitor linagliptin counteracts stroke in the normal and diabetic mouse brain: a comparison with glimepirideCopeptin and the risk of incident stroke, CHD and cardiovascular mortality in older men with and without diabetes: The British Regional Heart Study.GalR3 activation promotes adult neural stem cell survival in response to a diabetic milieu.Pituitary adenylate cyclase-activating polypeptide counteracts the impaired adult neural stem cell viability induced by palmitate.Impaired constitutive and regenerative neurogenesis in adult hyperglycemic zebrafish.Fractal analysis of circulating platelets in type 2 diabetic patients.Edaravone offers neuroprotection in a diabetic stroke model via inhibition of endoplasmic reticulum stress.Preferential effect of premorbid statins on atherothrombotic strokes through collateral circulation enhancement.Interactive effect of acute and chronic glycemic indexes for severity in acute ischemic stroke patients
P2860
Q26861493-2427EBEF-94F4-45EA-9CB0-69F9FE4070ADQ27341805-ED52C31D-58C0-4D63-8699-9018C627CC7AQ28081671-FFF33CFD-E040-4D5E-9386-D4A67EE5A0D9Q34015457-268EC0DD-8835-41F5-A0A4-B509F54D5899Q34342764-1B5F1B0C-80E2-4514-A005-AB8C414FB2E9Q35709472-F00A6A32-5858-4528-8129-5565CA0ECD44Q35976574-80DE3950-2484-4E74-8C0E-D902E7997CFBQ36421280-DE384BE1-8765-4029-B9EA-622850FEA0CBQ36653883-49C0999C-51B2-4BF2-98FF-FD79FE31E15DQ36720655-9482CAFD-5F13-4EC0-9857-C20216FFB3F2Q37143797-F93CD755-4243-40CF-8C60-CDBB64147E6AQ38313561-13B37E01-E965-409F-BD50-6212077C0554Q38329342-B3D0228B-882C-4D10-B177-88DC26C53196Q39658740-C2745454-EAED-4B8E-AEA0-2716D0A979C5Q45390540-F5B0E3D4-D29B-415E-8457-06E9E9B1687BQ45846630-1A8BF6CF-CEE8-4D33-8ECB-5B6F954A4338Q51316863-7926C907-4038-437B-A036-20C790253D22Q58801367-A45D1020-898E-44C6-AF86-F073895EF3C5
P2860
Reducing the risk of stroke in type 2 diabetes: pathophysiological and therapeutic perspectives.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 29 April 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Reducing the risk of stroke in ...... and therapeutic perspectives.
@en
Reducing the risk of stroke in ...... and therapeutic perspectives.
@nl
type
label
Reducing the risk of stroke in ...... and therapeutic perspectives.
@en
Reducing the risk of stroke in ...... and therapeutic perspectives.
@nl
prefLabel
Reducing the risk of stroke in ...... and therapeutic perspectives.
@en
Reducing the risk of stroke in ...... and therapeutic perspectives.
@nl
P2860
P1433
P1476
Reducing the risk of stroke in ...... and therapeutic perspectives.
@en
P2093
Dirk Sander
P2860
P2888
P304
P356
10.1007/S00415-009-5143-1
P50
P577
2009-04-29T00:00:00Z